162 related articles for article (PubMed ID: 35446336)
1. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.
Pijnappel EN; Suurmeijer JA; Koerkamp BG; Kos M; Siveke JT; Salvia R; Ghaneh P; van Eijck CHJ; van Etten-Jamaludin FS; Abrams R; Brasiuniene B; Büchler MW; Casadei R; van Laethem JL; Berlin J; Boku N; Conroy T; Golcher H; Sinn M; Neoptolemos JP; van Tienhoven G; Besselink MG; Wilmink JW; van Laarhoven HWM
JAMA Oncol; 2022 Jun; 8(6):929-937. PubMed ID: 35446336
[TBL] [Abstract][Full Text] [Related]
2. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.
Ter Veer E; van Rijssen LB; Besselink MG; Mali RMA; Berlin JD; Boeck S; Bonnetain F; Chau I; Conroy T; Van Cutsem E; Deplanque G; Friess H; Glimelius B; Goldstein D; Herrmann R; Labianca R; Van Laethem JL; Macarulla T; van der Meer JHM; Neoptolemos JP; Okusaka T; O'Reilly EM; Pelzer U; Philip PA; van der Poel MJ; Reni M; Scheithauer W; Siveke JT; Verslype C; Busch OR; Wilmink JW; van Oijen MGH; van Laarhoven HWM
Lancet Oncol; 2018 Mar; 19(3):e151-e160. PubMed ID: 29508762
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials.
Liu S; Li H; Xue Y; Yang L
PLoS One; 2023; 18(9):e0290888. PubMed ID: 37672511
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.
D'Angelo FA; Antolino L; La Rocca M; Petrucciani N; Magistri P; Aurello P; Ramacciato G
Med Oncol; 2016 Mar; 33(3):28. PubMed ID: 26883935
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Doppenberg D; van Dam JL; Han Y; Bonsing BA; Busch OR; Festen S; van der Harst E; de Hingh IH; Homs MYV; Kwon W; Lee M; Lips DJ; de Meijer VE; Molenaar IQ; Nuyttens JJ; Patijn GA; van Roessel S; van der Schelling GP; Suker M; Versteijne E; de Vos-Geelen J; Wilmink JW; van Eijck CHJ; van Tienhoven G; Jang JY; Besselink MG; Groot Koerkamp B;
Br J Surg; 2023 Sep; 110(10):1374-1380. PubMed ID: 37440421
[TBL] [Abstract][Full Text] [Related]
8. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J
PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030
[TBL] [Abstract][Full Text] [Related]
9. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages.
Tang K; Lu W; Qin W; Wu Y
Pancreatology; 2016; 16(1):28-37. PubMed ID: 26687001
[TBL] [Abstract][Full Text] [Related]
11. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).
Bockhorn M; Uzunoglu FG; Adham M; Imrie C; Milicevic M; Sandberg AA; Asbun HJ; Bassi C; Büchler M; Charnley RM; Conlon K; Cruz LF; Dervenis C; Fingerhutt A; Friess H; Gouma DJ; Hartwig W; Lillemoe KD; Montorsi M; Neoptolemos JP; Shrikhande SV; Takaori K; Traverso W; Vashist YK; Vollmer C; Yeo CJ; Izbicki JR;
Surgery; 2014 Jun; 155(6):977-88. PubMed ID: 24856119
[TBL] [Abstract][Full Text] [Related]
12. [Borderline resectable pancreatic cancer - a definition and effective treatment strategy].
Yokoyama Y; Ebata T; Igami T; Sugawara G; Takahashi Y; Kokuryo T; Tsunoda N; Fukaya M; Uehara K; Itatsu K; Yoshioka Y; Nagino M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):337-41. PubMed ID: 22421757
[TBL] [Abstract][Full Text] [Related]
13. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
14. Radiation therapy in borderline resectable pancreatic cancer: A review.
Turner KM; Delman AM; Kharofa JR; Smith MT; Choe KA; Olowokure O; Wilson GC; Patel SH; Sohal D; Ahmad SA
Surgery; 2022 Jul; 172(1):284-290. PubMed ID: 35034793
[TBL] [Abstract][Full Text] [Related]
15. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
Li X; Huang J; Jiang C; Chen P; Quan Q; Jiang Q; Li S; Guo G
Eur J Clin Pharmacol; 2023 Mar; 79(3):323-340. PubMed ID: 36576528
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.
Unno M; Hata T; Motoi F
Surg Today; 2019 Apr; 49(4):295-299. PubMed ID: 30877550
[TBL] [Abstract][Full Text] [Related]
17. [Evidence for Neoadjuvant Therapy in Resectable Pancreatic Cancer].
Nießen A; Büchler MW; Hackert T
Zentralbl Chir; 2022 Apr; 147(2):168-172. PubMed ID: 35378557
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
19. Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer.
Nakajima H; Yamaguchi J; Takami H; Hayashi M; Kodera Y; Nishida Y; Watanabe N; Onoe S; Mizuno T; Yokoyama Y; Ebata T
Int J Clin Oncol; 2023 May; 28(5):688-697. PubMed ID: 36872415
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
